Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy.
Ontology highlight
ABSTRACT: The response to neoadjuvant chemotherapy in breast cancer patients is usually assessed by pCR and RCB score. However, the prognostic value of these parameters is still in discussion. We showed recently that an epirubicin/docetaxel therapy is associated with an increase in the cell death marker high-mobility group box 1 protein (HMGB1) in the circulation. Here, we investigate whether this increase correlates with the long-term outcome. Thirty-six early breast cancer patients under neoadjuvant epirubicin/docetaxel combination chemotherapy were included in this study. To determine the immediate effect of this treatment on HMGB1, we collected blood samples before and 24-96 h after the initial dose. This time course was then compared to the 5-year follow-up of the patients. HMGB1 levels varied
SUBMITTER: Exner R
PROVIDER: S-EPMC5055166 | biostudies-literature | 2016 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA